Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar 15;33(6):901-908.
doi: 10.1093/bioinformatics/btw713.

Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications

Affiliations
Free PMC article

Predict drug permeability to blood-brain-barrier from clinical phenotypes: drug side effects and drug indications

Zhen Gao et al. Bioinformatics. .
Free PMC article

Abstract

Motivation: Blood-Brain-Barrier (BBB) is a rigorous permeability barrier for maintaining homeostasis of Central Nervous System (CNS). Determination of compound's permeability to BBB is prerequisite in CNS drug discovery. Existing computational methods usually predict drug BBB permeability from chemical structure and they generally apply to small compounds passing BBB through passive diffusion. As abundant information on drug side effects and indications has been recorded over time through extensive clinical usage, we aim to explore BBB permeability prediction from a new angle and introduce a novel approach to predict BBB permeability from drug clinical phenotypes (drug side effects and drug indications). This method can apply to both small compounds and macro-molecules penetrating BBB through various mechanisms besides passive diffusion.

Results: We composed a training dataset of 213 drugs with known brain and blood steady-state concentrations ratio and extracted their side effects and indications as features. Next, we trained SVM models with polynomial kernel and obtained accuracy of 76.0%, AUC 0.739, and F 1 score (macro weighted) 0.760 with Monte Carlo cross validation. The independent test accuracy was 68.3%, AUC 0.692, F 1 score 0.676. When both chemical features and clinical phenotypes were available, combining the two types of features achieved significantly better performance than chemical feature based approach (accuracy 85.5% versus 72.9%, AUC 0.854 versus 0.733, F 1 score 0.854 versus 0.725; P < e -90 ). We also conducted de novo prediction and identified 110 drugs in SIDER database having the potential to penetrate BBB, which could serve as start point for CNS drug repositioning research.

Availability and implementation: https://github.com/bioinformatics-gao/CASE-BBB-prediction-Data.

Contact: rxx@case.edu.

Supplementary information: Supplementary data are available at Bioinformatics online.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mechanisms of drugs passing BBB and the scope of prediction methods. Right part shows the mechanisms for drug passing BBB, left part shows the scope of drug clinical phenotype based and chemical feature based BBB permeability prediction methods
Fig. 2
Fig. 2
Schema of experimental steps for prediction of drugs’ permeability to Blood–Brain-Barrier.

Similar articles

Cited by

References

    1. Abraham M.H. et al. (2006) A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data. J. Pharm. Sci., 95, 2091–2100. - PubMed
    1. Ahr H.J. et al. (1989) Pharmacokinetics of acarbose. Part II: Distribution to and elimination from tissues and organs following single or repeated administration of [14C] acarbose to rats and dogs. Arzneimittel-Forschung, 39, 1261–1267. - PubMed
    1. Andresen L.P.V. (2010) Review article: rifaximin, a minimally absorbed oral antibacterial, for the treatment of travellers’ diarrhoea. Alimentary Pharm. Ther., 31, 1155–1164. - PubMed
    1. Banks W.A. (2004) The source of cerebral insulin. Eur. J. Pharm., 19, 5–12. - PubMed
    1. Bickel U. (2005) How to measure drug transport across the blood–brain barrier. NeuroRx, 2, 15–26. - PMC - PubMed

Publication types

Substances